XERS

Xeris Biopharma Holdings Inc

10.20

Oct 23 • 3:59 PM ET -0.66 (-6.08%)

10.25

Aftermarket • 7:30 PM ET +0.05 (0.47%)

Healthcare Drug Manufacturers - Specialty & Generic USA Small NASD

Peers: AMPH CORT ETON AMLX ANIP SUPN COLL RYTM HRMY ASND

| Held by: VTI IWM VXF IWO XPH FESM SCHA VTWO FYC DFAS

Scroll to Statements

Index	RUT
Market Cap	1.86B
Enterprise Value	2.03B
Income	-17.16M
Sales	335.41M
Book/sh	-0.06
Cash/sh	0.67
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	435
IPO	Jun 21, 2018

P/E	-
Forward P/E	29.63
PEG	-
P/S	5.54
P/B	-
P/C	15.27
P/FCF	33.41
EV/EBITDA	41.04
EV/Sales	6.04
Quick Ratio	1.02
Current Ratio	1.45
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-0.10
EPS next Y	0.34
EPS next Q	0.03
EPS this Y	55.91%
EPS next Y	6785.72%
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	38.33% 70.20%
EPS Y/Y TTM	54.68%
Sales Y/Y TTM	36.33%
EPS Q/Q	-1387.60%
Sales Q/Q	28.74%
Earnings	Nov 05 BMO
EPS/Sales Surpr.	-1587.60% 2.19%

Insider Own	5.05%
Insider Trans	-4.03%
Inst Own	60.15%
Inst Trans	1.92%
ROA	-4.60%
ROE	-
ROIC	-8.19%
Gross Margin	83.34%
Oper. Margin	10.91%
Profit Margin	-5.12%
SMA20	0.29%
SMA50	11.84%
SMA200	37.25%
Trades

Shs Outstand	173.59M
Shs Float	173.10M
Short Float	4.16%
Short Ratio	3.15
Short Interest	7.20M
52W High	11.41 -10.64%
52W Low	5.25 94.29%
Volatility	5.87% 6.11%
ATR (14)	0.54
RSI (14)	54.24
Beta	0.83
Rel Volume	1.04
Avg Volume	2.28M
Volume	2,372,154

Perf Week	-1.07%
Perf Month	13.97%
Perf Quarter	24.24%
Perf Half Y	68.60%
Perf YTD	29.94%
Perf Year	11.72%
Perf 3Y	503.55%
Perf 5Y	460.44%
Perf 10Y	-
Recom	1.38
Target Price	12.86
Prev Close	10.86
Price	10.20
Change %	-6.08%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Overweight	$9
Aug-12-25	Resumed	H.C. Wainwright	Buy	$10
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral	$3
Mar-28-24	Initiated	Oppenheimer	Outperform	$5
Aug-28-23	Initiated	Craig Hallum	Buy	$4.50
Oct-21-22	Initiated	Jefferies	Buy	$4
Apr-28-22	Initiated	Craig Hallum	Buy	$6.50
Nov-17-21	Initiated	SVB Leerink	Outperform	$6
Oct-29-21	Initiated	H.C. Wainwright	Buy	$4
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$11
Feb-18-20	Initiated	Piper Sandler	Overweight	$12
Jul-16-18	Initiated	RBC Capital Mkts	Outperform	$24
Jul-16-18	Initiated	Leerink Partners	Outperform	$24
Jul-16-18	Initiated	Jefferies	Buy	$23

Show Previous Ratings

Oct-22-26 08:00AM	Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 (Business Wire)
Oct-15-26 08:00AM	Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings (Business Wire)
Oct-02-26 05:00PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) +11.56%
Sep-29-26 04:17PM	Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports (Investing.com)
02:01PM	Xeris Biopharma Reportedly Draws Takeover Interest But Firm Says Its Not For Sale (Stocktwits)
07:30AM	Loading…
Aug-26-26 07:30AM	Xeris Announces Details for XP-8121 Program Overview Webinar (Business Wire)
Aug-06-26 07:13PM	Xeris Biopharma Holdings Inc (XERS) (Q2 2026) Earnings Call Highlights: Record Revenue and ... (GuruFocus.com) -9.25% +7.74%
07:18AM	Xeris Biopharma: Q2 Earnings Snapshot (Associated Press)
07:00AM	Xeris Biopharma Reports Second Quarter 2026 Financial Results (Business Wire)
Jul-23-26 07:30AM	Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 (Business Wire)
Jul-02-26 04:05PM	Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jun-30-26 07:00AM	Xeris Announces Updates to Its Board of Directors (Business Wire)
Jun-11-26 04:39PM	Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS (Business Wire)
07:00AM	Xeris Biopharma Announces Private Exchange of Convertible Notes (Business Wire)
May-07-26 07:18AM	Xeris Biopharma: Q1 Earnings Snapshot (Associated Press)
07:00AM	Loading…
07:00AM	Xeris Biopharma Reports First Quarter 2026 Financial Results (Business Wire)
Apr-23-26 07:30AM	Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026 (Business Wire)
Apr-03-26 04:15PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Mar-02-26 04:01PM	Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
10:37AM	Xeris Biopharma Q4 Earnings Call Highlights (MarketBeat)
09:30AM	Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:06AM	Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:13AM	Xeris Biopharma: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance (Business Wire)
Feb-27-26 12:29PM	Why Are Shares Of Xeris Biopharma Falling Friday? (Benzinga) -9.20%
Feb-26-26 05:55PM	Xeris Biopharma Subsidiaries File Recorlev Patent Infringement Lawsuit (Business Wire)
12:15PM	BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates (Zacks)
09:15AM	Unlocking Q4 Potential of Xeris Biopharma (XERS): Exploring Wall Street Estimates for Key Metrics (Zacks)
05:35AM	TheStreet Pro: Four Stocks that Will Win Despite Irrational Panic over AI (TipRanks)
Feb-17-26 07:30AM	Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026 (Business Wire)
07:00AM	Loading…
Jan-08-26 07:00AM	Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue (Business Wire) +12.76%
Jan-02-26 04:15PM	Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -6.37%
Dec-31-25 07:09PM	Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday (Motley Fool) +7.39%
Dec-18-25 01:13PM	Xeris Biopharma Holdings, Inc. (XERS): A Bull Case Theory (Insider Monkey)
Dec-01-25 07:00AM	Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application (Business Wire)
Nov-06-25 09:30AM	Xeris Biopharma (XERS) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks) -21.88%
08:30AM	Xeris Biopharma (XERS) Reports Break-Even Earnings for Q3 (Zacks)
07:00AM	Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025 (Business Wire)
Oct-30-25 06:45PM	Plus Therapeutics (PSTV) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Oct-23-25 07:30AM	Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025 (Business Wire)
Oct-20-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Xeris Biopharma (XERS) is a Great Choice (Zacks)
09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? (Zacks)
Oct-16-25 09:06AM	Xeris Biopharma (XERS) Surges 14.2%: Is This an Indication of Further Gains? (Zacks)
Oct-13-25 07:58AM	Beat the Market the Zacks Way: MariMed, Xeris Biopharma, Lam Research in Focus (Zacks)
Oct-03-25 04:15PM	Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:00PM	Xeris Biopharma (XERS) is a Great Momentum Stock: Should You Buy? (Zacks)
09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? (Zacks)
Sep-09-25 12:00PM	What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now? (Zacks)
Aug-29-25 05:09AM	Xeris Biopharma Holdings, Inc. (XERS) Reports Record $71.5M Q2 Revenue (Insider Monkey)
Aug-25-25 07:00AM	Xeris Announces Orange Book Listing of U.S. Patent for Recorlev (Business Wire)
Aug-12-25 12:00PM	Xeris Biopharma (XERS) Upgraded to Buy: Here's Why (Zacks)
09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +20.22%
09:30AM	Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:35AM	Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:32AM	Xeris Biopharma: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance (Business Wire)
Jul-31-25 07:30AM	Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
Jul-03-25 08:19AM	Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last? (Zacks)
Jun-03-25 07:30AM	Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day (Business Wire) -7.92%
May-20-25 07:30AM	Xeris Announces Details for Analyst & Investor Day (Business Wire)
May-12-25 03:54PM	Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now (Insider Monkey)
May-09-25 03:21AM	Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
May-08-25 08:20AM	Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +15.18%
07:17AM	Xeris Biopharma: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Record First Quarter 2025 Financial Results (Business Wire)
May-07-25 12:08PM	Xeris Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
11:51AM	Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings (Seeking Alpha)
May-05-25 05:30PM	Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates (Zacks) -7.33%
May-01-25 07:00AM	Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 (Business Wire)
Apr-22-25 06:46PM	Is Xeris Biopharma Holdings Inc. (XERS) the Best Multibagger Penny Stock to Buy According to Billionaires? (Insider Monkey)
Apr-17-25 07:00AM	Bright Peak Therapeutics Appoints John Schmid to its Board of Directors (GlobeNewswire)
Mar-28-25 08:00AM	Xeris Announces Changes to Its Board of Directors (Business Wire)
Mar-27-25 10:18AM	Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-20-25 10:13AM	Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? (Zacks)
Mar-19-25 04:49PM	Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game (InsiderMonkey) +5.56%
Mar-17-25 08:00AM	Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx (glucagon) for Use as a Diagnostic Aid (Business Wire)
Mar-07-25 02:08AM	Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ... (GuruFocus.com)
Mar-06-25 09:30AM	Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings (Zacks) +9.55%
08:15AM	Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:22AM	Xeris Biopharma: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance (Business Wire)
Feb-27-25 07:00AM	Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025 (Business Wire)
Feb-26-25 10:00AM	Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-24-25 08:00AM	Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer (Business Wire)
Feb-05-25 08:00AM	Xeris to Participate in Upcoming Investor Conferences (Business Wire)
Jan-21-25 09:00AM	The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness (PR Newswire)
Jan-11-25 07:27AM	Xeris Biopharma raises FY24 revenue view to $203M from $198M-$202M (TipRanks)
Jan-10-25 07:00AM	Xeris Expects to Exceed Full-Year 2024 Financial Guidance (Business Wire)
Jan-06-25 04:15PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.37%
Nov-26-24 07:00AM	Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-09-24 02:06AM	Xeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Nov-08-24 09:30AM	Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:10AM	Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Xeris Biopharma: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Third Quarter 2024 Financial Results (Business Wire)
Oct-31-24 08:00AM	Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024 (Business Wire)
Oct-04-24 04:05PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pieper Steven	See Remarks	Oct 01 '26	Sale	9.41	5,000	47,036	1,351,053	Oct 02 04:54 PM
McCulloch Kevin	See Remarks	Oct 01 '26	Sale	9.41	15,000	141,120	1,599,208	Oct 02 04:54 PM
Hecht Beth	See Remarks	Oct 01 '26	Sale	9.41	16,666	156,792	1,111,130	Oct 02 04:54 PM
BETH HECHT	Officer	Oct 01 '26	Proposed Sale	9.56	16,666	159,327		Oct 01 04:26 PM
McCulloch Kevin	See Remarks	Sep 28 '26	Sale	10.00	25,000	250,000	1,614,208	Sep 29 04:59 PM
KEVIN MCCULLOCH	Officer	Sep 28 '26	Proposed Sale	9.10	70,000	637,000		Sep 28 04:19 PM
McCulloch Kevin	See Remarks	Sep 01 '26	Sale	8.49	15,000	127,308	1,639,208	Sep 01 06:21 PM
Hecht Beth	See Remarks	Sep 01 '26	Sale	8.49	16,666	141,434	1,127,796	Sep 01 06:21 PM
Pieper Steven	See Remarks	Sep 01 '26	Sale	8.50	5,000	42,500	1,356,053	Sep 01 06:20 PM
Pieper Steven	See Remarks	Aug 12 '26	Sale	8.50	5,000	42,500	1,361,053	Aug 12 04:44 PM
STEVEN PIEPER	Officer	Aug 12 '26	Proposed Sale	8.39	20,000	167,800		Aug 12 04:37 PM
McCulloch Kevin	See Remarks	Aug 03 '26	Sale	8.02	15,000	120,240	1,676,126	Aug 04 05:30 PM
Hecht Beth	See Remarks	Aug 03 '26	Sale	8.01	16,666	133,553	1,144,462	Aug 04 05:16 PM
Pieper Steven	See Remarks	Jul 07 '26	Sale	8.52	27,600	235,276	1,366,053	Jul 07 05:11 PM
Pieper Steven	See Remarks	Jul 06 '26	Sale	8.50	17,400	147,900	1,393,653	Jul 07 05:11 PM
STEVEN PIEPER	Officer	Jul 07 '26	Proposed Sale	8.37	27,600	231,012		Jul 07 04:37 PM
STEVEN PIEPER	Officer	Jul 06 '26	Proposed Sale	8.28	17,400	144,072		Jul 06 04:39 PM
McCulloch Kevin	See Remarks	Jul 01 '26	Sale	8.03	90,000	722,511	1,691,126	Jul 02 04:40 PM
Hecht Beth	See Remarks	Jul 01 '26	Sale	8.03	16,666	133,860	1,161,128	Jul 02 04:38 PM
BETH HECHT	Officer	Jul 01 '26	Proposed Sale	7.92	49,998	395,984		Jul 01 04:51 PM
KEVIN MCCULLOCH	Officer	Jul 01 '26	Proposed Sale	7.92	120,000	950,400		Jul 01 04:21 PM
PERSKY MARLA	Director	Jun 03 '26	Sale	5.90	15,500	91,433	126,500	Jun 05 06:29 PM
HALKUFF DAWN	Director	Jun 04 '26	Sale	6.09	20,000	121,886	95,000	Jun 05 06:18 PM
BORMANN-KENNEDY BARBARA-JEAN A	Director	Jun 04 '26	Sale	6.09	16,000	97,507	126,500	Jun 05 06:18 PM
JOHNSON JOHN	Director	Jun 04 '26	Sale	6.09	15,000	91,422	683,083	Jun 05 06:17 PM
DAWN HALKUFF	Director	Jun 04 '26	Proposed Sale	5.89	20,000	117,800		Jun 04 04:33 PM
JOHN H JOHNSON	Director	Jun 04 '26	Proposed Sale	5.89	15,000	88,350		Jun 04 04:33 PM
Barbara-Jean Bormann-Kennedy	Director	Jun 04 '26	Proposed Sale	5.89	16,000	94,240		Jun 04 04:32 PM
MARLA PERSKY	Director	Jun 03 '26	Proposed Sale	6.00	15,500	93,000		Jun 03 04:25 PM
Hecht Beth	See Remarks	Jun 01 '26	Sale	6.06	16,667	100,982	1,176,506	Jun 02 06:05 PM
Hecht Beth	See Remarks	May 01 '26	Sale	6.23	16,667	103,805	1,193,173	May 01 05:50 PM
Hecht Beth	See Remarks	Apr 01 '26	Sale	5.99	16,667	99,859	1,209,840	Apr 03 05:45 PM
Brady James Aloysius	Director	Mar 30 '26	Sale	5.54	10,834	60,036	89,166	Apr 01 05:54 PM
JAMES BRADY	Director	Mar 30 '26	Proposed Sale	5.40	10,834	58,504		Mar 30 05:31 PM
McCulloch Kevin	See Remarks	Mar 12 '26	Option Exercise	4.09	48,898	199,992	1,777,725	Mar 16 06:11 PM
Pieper Steven	See Remarks	Mar 05 '26	Option Exercise	4.71	41,927	197,308	1,408,940	Mar 05 07:18 PM
Hecht Beth	See Remarks	Mar 02 '26	Sale	6.25	16,667	104,086	1,226,507	Mar 04 05:28 PM
BETH HECHT	Officer	Mar 02 '26	Proposed Sale	6.12	66,668	408,008		Mar 02 04:36 PM
Hecht Beth	See Remarks	Feb 02 '26	Sale	7.45	16,667	124,147	1,243,174	Feb 02 06:11 PM
McCulloch Kevin	See Remarks	Jan 08 '26	Sale	8.00	15,000	120,000	1,685,426	Jan 09 05:34 PM
KEVIN MCCULLOCH	Officer	Jan 08 '26	Proposed Sale	7.21	60,000	432,600		Jan 08 04:22 PM
Shannon John Patrick Jr	See Remarks	Jan 05 '26	Option Exercise	1.63	92,301	149,998	2,797,647	Jan 06 06:14 PM
Shannon John Patrick Jr	See Remarks	Jan 05 '26	Sale	7.08	24,907	176,257	2,705,346	Jan 06 06:14 PM
Hecht Beth	See Remarks	Jan 02 '26	Sale	7.43	16,667	123,776	1,308,103	Jan 05 06:01 PM
JOHN H JOHNSON	Director	Dec 19 '25	Proposed Sale	7.22	135,402	977,034		Dec 19 06:15 PM
JOHNSON JOHN	Director	Dec 19 '25	Sale	7.22	135,400	977,019	698,083	Dec 19 05:17 PM
BORMANN-KENNEDY BARBARA-JEAN A	Director	Dec 12 '25	Sale	7.09	15,000	106,414	142,500	Dec 15 05:24 PM
BARBARA-JEAN A BORMANN-KENNEDY	Director	Dec 12 '25	Proposed Sale	7.01	15,000	105,150		Dec 12 04:20 PM
Hecht Beth	See Remarks	Dec 01 '25	Sale	7.01	16,667	116,781	1,320,176	Dec 02 05:14 PM
Shannon John Patrick Jr	See Remarks	Nov 14 '25	Option Exercise	1.55	87,100	135,005	2,730,253	Nov 17 05:58 PM
Shannon John Patrick Jr	See Remarks	Nov 13 '25	Option Exercise	1.55	8,970	13,904	2,666,395	Nov 17 05:58 PM
Shannon John Patrick Jr	See Remarks	Nov 13 '25	Sale	7.46	23,242	173,402	2,643,153	Nov 17 05:58 PM
Hecht Beth	See Remarks	Nov 11 '25	Sale	7.40	16,667	123,296	1,336,843	Nov 13 06:59 PM
JOHN SHANNON	Director	Nov 13 '25	Proposed Sale	7.59	48,149	365,451		Nov 13 04:25 PM
BETH HECHT	Officer	Nov 11 '25	Proposed Sale	7.72	66,668	514,677		Nov 12 07:02 AM

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Chairman & CEOMr. John P. Shannon

President & COOMr. Kevin McCulloch

Chief Financial OfficerMr. Steven M. Pieper

Chief Legal Officer & Corporate SecretaryMs. Beth P. Hecht J.D.

M.D.Dr. Anh T. Nguyen M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XERS

Xeris Biopharma Holdings Inc

Upgrade your Finviz experience